Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.485 SEK | +10.94% | -4.24% | -32.84% |
Apr. 26 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
Mar. 13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
Sales 2024 * | 60.55M 5.59M | Sales 2025 * | 167M 15.41M | Capitalization | 262M 24.18M |
---|---|---|---|---|---|
Net income 2024 * | -191M -17.64M | Net income 2025 * | -146M -13.49M | EV / Sales 2024 * | 2.12 x |
Net cash position 2024 * | 133M 12.3M | Net Debt 2025 * | 5.24M 484K | EV / Sales 2025 * | 1.6 x |
P/E ratio 2024 * |
-1.84
x | P/E ratio 2025 * |
-2.73
x | Employees | 127 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.61% |
Latest transcript on Q-linea AB
1 day | +10.94% | ||
1 week | -4.24% | ||
Current month | -4.24% | ||
1 month | +17.49% | ||
3 months | -2.17% | ||
6 months | -22.34% | ||
Current year | -32.84% |
Managers | Title | Age | Since |
---|---|---|---|
Director of Finance/CFO | 70 | 23-04-30 | |
Henrik Jacobsson
COO | Chief Operating Officer | 55 | 21-12-31 |
Chief Tech/Sci/R&D Officer | 48 | 19-07-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 62 | 11-12-31 | |
Founder | 54 | 08-03-31 | |
Director/Board Member | 70 | 17-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 2.485 | +10.94% | 370 521 |
24-05-06 | 2.24 | -8.94% | 431,418 |
24-05-03 | 2.46 | -3.72% | 335,347 |
24-05-02 | 2.555 | -1.54% | 921,673 |
24-04-30 | 2.595 | -10.82% | 751,560 |
Delayed Quote Nasdaq Stockholm, May 07, 2024 at 09:01 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.84% | 24.22M | |
-15.73% | 18.77B | |
-41.10% | 2.9B | |
+24.02% | 1.97B | |
+8.62% | 1.82B | |
+26.03% | 1.25B | |
-7.74% | 1.06B | |
-18.61% | 936M | |
-1.33% | 770M | |
-23.76% | 639M |
- Stock Market
- Equities
- QLINEA Stock